BCLI News and Press, Brainstorm Cell Therapeutics Inc. From 11/13/23

2023-11-13 12:54:20 ET More on BrainStorm Cell Therapeutics Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks Brainstorm realigns resources to support NurOwn development Brainstorm to pull marketing application for ALS therapy ...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal ri...

BrainStorm to Announce Third Quarter 2023 Financial Results and Provide a Corporate Update PR Newswire NEW YORK , Nov. 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseas...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal ri...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal ri...

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Brainstorm C...

2023-10-24 08:17:04 ET BrainStorm Cell Therapeutics ( NASDAQ: BCLI ) on Tuesday announced a strategic realignment to support accelerated development of NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm ( BCLI ) holds the rights to clinical dev...

BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn® for the Treatment of ALS PR Newswire - Resource consumption will be reduced by 50% to accelerate ALS development - Plans underway for registrational Phase 3b U.S. clinical trial ...

2023-10-18 13:28:57 ET More on BrainStorm Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2023 Earnings Call Transcript FDA advisory panel votes against BrainStorm ALS therapy B...

BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS PR Newswire - Path forward for ALS is a registrational Phase 3b U.S. clinical trial - - Biologics License Application to be withdrawn without prejudice - ...